Theragen Buys Neurotech North America

Leesburg, Va.-based Theragen LLC, which makes noninvasive medical devices, has acquired Neurotech North America (NA), formerly a part of BioMedical Research (BMR) Group Ltd. based in Galway, Ireland. Neurotech makes noninvasive stimulation products for orthopedics and spine indications. The purchase includes commercial rights to Rest of the World assets, excluding Germany, Switzerland and Austria.

Neurotech NA’s primary products include Kneehab XP, cleared by the U.S. Food and Drug Administration for quadriceps strengthening; and Neurotech Recovery Back, a transcutaneous electrical nerve stimulation (TENS) and neuromuscular electrical nerve stimulation (NMES) technology cleared for the lower back.

“Neurotech’s products are proven and possess an exceptional safety record,” said Gary Grenter, president and CEO of Theragen. “After focusing the past 18 months on our research and development efforts, we are excited about entering the non-invasive therapeutics industry with these excellent products.”

“Theragen’s mission is to develop non-invasive therapeutic solutions using electrical, mechanical and other forms of energy that will provide relief for sufferers both prior to and post surgical intervention,” said Kimball Chen, Theragen chairman of the board. “This acquisition demonstrates our commitment to this mission as we incorporate Neurotech’s world-class technology, research and development into our portfolio.”

“I am pleased to be working again with Gary Grenter and J. Chris McAuliffe, our company’s executive vice president and chief operating officer,” added Chen. “This leadership team saw great success together at Biolectron and today’s acquisition marks the first of many significant achievements to come for Theragen.”

Biolectron Inc. is a Las Vegas, Nev.-based spine device company. Grenter served as CEO there from 1998 to 2001, and McAuliffe served there as vice president of sales from 1993 to 2000.